A Study of Autologous Induced Islet Body With Type 1 Diabetes

General Information

Summary This is a single centre, single arm, open-label study, to investigate the safety and efficacy of Autologous induced islet body With Type 1 diabetes.
Clinical trials phase Other
Start date (estimated) 2019-01-01
End date (estimated) 2021-01-31
Clinical feature
Label type 1 diabetes mellitus
Link http://purl.obolibrary.org/obo/DOID_9744
Description A diabetes mellitus that is characterized by destruction of pancreatic beta cells resulting in absent or extremely low insulin production.; Xref MGI. OMIM mapping confirmed by DO. [SN].

Administrative Information

NCT number NCT03728296
ICTRP weblink https://trialsearch.who.int/Trial2.aspx?TrialID=NCT03728296
Other study identifiers
Name islet body-01
Source weblink https://clinicaltrials.gov/ct2/show/NCT03728296
Public contact
Email allife@allifetech.com
Public email allife@allifetech.com
City Beijing
Sponsors Allife Medical Science and Technology Co., Ltd.


Which differentiated cell type is used
Label islet of Langerhans
Link http://purl.obolibrary.org/obo/UBERON_0000006
Description The clusters of hormone-producing cells that are scattered throughout the pancreas.


Recruitment Status Not yet recruiting
Estimated number of participants 20